ZD6474(Vandetanib) + Alimta Combo Study

Phase 1 Completed 21 enrolled Genzyme, a Sanofi Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main purpose of this trial is to look to see if adding ZD6474 (100 mg or 300mg tablets) to Alimta chemotherapy in patients with non-small cell lung cancer is safe and will help control their symptoms and disease better than the chemotherapy alone.

Timeline

Start: 2005-07
Primary completion: 2006-05
Completion: 2011-10

Publications

Background de Boer R, Humblet Y, Wolf J, Nogova L, Ruffert K, Milenkova T, Smith R, Godwood A, Vansteenkiste J. An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Ann Oncol. 2009 Mar;20(3):486-91. doi: 10.1093/annonc/mdn674. Epub 2008 Dec 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pemetrexed	Small molecule	—	Intravenous
Subject	Vandetanib	Small molecule	100 mg	Oral
Subject	Vandetanib	Small molecule	300 mg	Oral

ZD6474(Vandetanib) + Alimta Combo Study

Summary

Timeline

Publications

Drugs

Indications